Welcome to our dedicated page for Inverse VIX S/T Futs ETNs due Mar22,2045 SEC filings (Ticker: VYLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inverse VIX Short-Term Futures ETNs due March 22, 2045 (VYLD) brings together U.S. regulatory documents in which this security is formally identified. In multiple Form 8-K current reports filed by JPMorgan Chase & Co., VYLD appears in the table of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
In those filings, the Title of each class is given as the Guarantee of Inverse VIX Short-Term Futures ETNs due March 22, 2045 of JPMorgan Chase Financial Company LLC, the Trading Symbol is listed as VYLD, and the Name of each exchange on which registered is NYSE Arca, Inc. The same tables also list JPMorgan Chase & Co. common stock, depositary shares representing interests in various preferred stock series, and other guaranteed notes and ETNs.
Through this page, users can access the underlying Form 8-K reports and related exhibits where VYLD is mentioned. These filings may cover topics such as earnings releases, changes to by-laws, or the closing of public offerings of other notes and subordinated debt, with VYLD included in the standardized disclosure of registered securities.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of each document in plain language, while still preserving access to the full official text from EDGAR. Users can quickly see where VYLD appears in the filing, understand the context of the report, and navigate to other securities listed in the same disclosure table.
For deeper analysis, investors can review successive filings over time to confirm that VYLD remains listed as a registered security and to see how it is grouped with other instruments issued or guaranteed by JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC.
JPMorgan Chase & Co.'s Chief Information Officer Lori A. Beer reported an open-market sale of company stock. On February 17, 2026, she sold 2,047 shares of common stock at a price of $306.4031 per share. After this transaction, she directly beneficially owned 60,452 shares of JPMorgan Chase common stock.
JPMorgan Chase & Co. Chief Financial Officer Jeremy Barnum reported an open-market sale of 2,892 shares of common stock on February 17, 2026 at $306.4167 per share. Following this transaction, he directly owned 23,804 shares of JPMorgan Chase common stock.
JPMorgan Chase executive Lake Marianne reported an open-market sale of 3,907 shares of common stock at $306.4137 per share. The transaction was executed on February 17, 2026 through Grantor Retained Annuity Trusts, which hold 137,299 shares indirectly after the sale.
Separately from these GRAT holdings, she is shown with 48,017 shares held directly and 64,271 shares held indirectly through a Family Trust. Footnote disclosures explain earlier February 2026 transfers among a GRAT, a Family Trust, and the Grantor that were treated as exempt under Rule 16a-13.
JPMorgan Chase & Co. General Counsel Stacey Friedman reported an indirect sale of common stock through a grantor retained annuity trust (GRAT). On February 17, 2026, the GRAT sold 3,404 shares at $306.3999 per share in an open-market transaction.
Following this sale, the GRAT held 61,949 shares of JPMorgan Chase common stock indirectly for Friedman. Separately, she held 50,136 shares directly, and an additional 13,604 shares were held indirectly in a trust.
JPMorgan Chase insider Stacey Friedman has filed a Form 144 indicating an intent to sell 3,404 shares of common stock. The planned sale, through J.P. Morgan Securities LLC on the NYSE, has an aggregate market value of
The shares to be sold were originally acquired on
A shareholder filed a Form 144 notice to sell 3,907 shares of common stock, with an aggregate market value of $1,197,158.15. The shares are to be sold through J.P. Morgan Securities LLC on the NYSE around 02/17/2026. These shares were acquired on 01/13/2022 as equity compensation awards from the issuer. The filer also sold 3,908 shares of the same common stock on 01/16/2026 for gross proceeds of $1,222,353.41, as disclosed for sales during the past three months.
Douglas Petno filed a Form 144 notice to sell 3,487 shares of JPM common stock through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $1,068,428.91. The filing lists 2,696,272,576 shares of common stock outstanding.
The shares to be sold were acquired on 01/13/2026 as equity compensation awards from the issuer. The notice also reports that during the past three months, Petno sold 3,487 shares of common stock on 01/16/2026 for gross proceeds of $1,090,727.70.
JPM common stock holder Mary Erdoes filed a notice to sell 5,731 shares of common stock, with an aggregate market value of
The 5,731 shares to be sold were acquired on
JPMorgan Chase investor plans a small insider sale. A holder intends to sell 2,047 shares of JPMorgan Chase common stock through J.P. Morgan Securities LLC on the NYSE, with an approximate sale date of February 17, 2026 and an aggregate market value of
The shares were acquired on January 13, 2026 as equity compensation awards from the issuer. The filing also notes that a person named Lori Beer sold 2,047 common shares on January 16, 2026, generating gross proceeds of
JPMorgan Chase insider plans and reports stock sales. A Form 144 notice covers a proposed sale of 2,892 shares of common stock through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $886,156.96, against 2,696,272,576 shares outstanding.
The shares were acquired on January 13, 2026 as equity compensation from the issuer. The filing also notes that Jeremy Barnum sold 2,893 shares of $1 par value common stock on January 16, 2026 for gross proceeds of $904,889.57. The filer represents they are not aware of undisclosed material adverse information.